SAR-CoV-2 DNA vaccine and method of administering thereof
AssigneeThe Government of the United States, as represented by the Secretary of the Army
InventorJay W. Hooper
Life of this patent
Estimating the term…
Abstract
The current disclosure provides a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-based DNA vaccine capable of eliciting immune response to a SARS-CoV-2 in a human subject upon administration. Also provided is a method of eliciting an immune response to a SARS-CoV-2 in a human subject by administering the SARS-CoV-2 spike-based DNA vaccine, for example, intramuscularly using a jet injector.
Claims14
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-based DNA composition comprising a recombinant DNA construct in a plasmid, wherein the recombinant DNA construct comprises SEQ ID NO:
- 1 as a human codon-optimized nucleic acid sequence encoding a SARS-CoV-2 spike protein.
Dependencies are inferred from the claim text.